The announcement that Acambis has won a $425 million, 10-year contract to supply the U.S. government with its smallpox vaccine, along with a new share placement, will provide the company with enough cash to fund operations for the medium term. To win the contract, Acambis had to agree to produce the vaccine in the U.S. Report [1]